[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545397":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":22,"locations":30,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":10,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Cairo University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Tuberculous Patients",null,[12],"Other: Anti Tuberculosis Drug",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"Anti Tuberculosis Drug","1. Estimate the prevalence of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients.\n2. Assess the outcome of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients (response to treatment and the prevalence of life-threatening events).",[9],[19],{"name":20,"affiliation":5,"role":21},"Soha Aly Elmorsy","PRINCIPAL_INVESTIGATOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Omnia Azmy Nabeh, MD","CONTACT","01066969673","omnia.azmy@kasralainy.edu.eg",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":10},"Hoda Mohamed Abdel-Hamid",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Omnia Azmy Nabeh","RECRUITING","Cairo","11562","Egypt","EG",{"type":39,"coordinates":40},"Point",[41,42],31.24967,30.06263,{"lat":42,"lon":41},[45],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},{"type":21,"investigatorFullName":32,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Dr.","100545397","drug-drug-interactions-with-anti-tuberculous-drugs-100545397",false,"NCT06381375","Drug-drug Interactions With Anti-tuberculous Drugs","Assessment of the Prevalence and the Outcome of Prescribing Drugs Known to Have Major Drug-Drug Interactions With Anti-tuberculous Drugs Among Kasr Alainy Tuberculous Patients","Inclusion Criteria:\n\n* All patients diagnosed with tuberculosis and referred to Tuberculosis outpatient clinic, Kasr Alainy Faculty of Medicine, Cairo University, starting after the obtaining of the Scientific\u002FEthical approval of the study protocol.\n\nExclusion Criteria:\n\n* Refusal by the patient\u002Fpatient's guardian to participate in this study","ALL",{"count":57,"type":58},400,"ESTIMATED","OBSERVATIONAL","This study aims to assess the prevalence and the outcome of prescribing drugs known to have major drug-drug interactions with anti-tuberculous drugs among Kasr Alainy tuberculous patients.",[62],"Drug-drug Interaction","2024-08-20",{"date":65,"type":66},"2024-08-22","ACTUAL",{"date":68,"type":66},"2024-04-30",{"date":70,"type":58},"2025-02-15",{"name":5,"class":6},1]